These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Ravindran R; Maji M; Ali N Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194 [TBL] [Abstract][Full Text] [Related]
10. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603 [TBL] [Abstract][Full Text] [Related]
11. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700 [TBL] [Abstract][Full Text] [Related]
12. An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes. Khan MAA; Ami JQ; Faisal K; Chowdhury R; Ghosh P; Hossain F; Abd El Wahed A; Mondal D Parasit Vectors; 2020 Apr; 13(1):196. PubMed ID: 32295617 [TBL] [Abstract][Full Text] [Related]
13. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C Front Immunol; 2018; 9():465. PubMed ID: 29599776 [TBL] [Abstract][Full Text] [Related]
15. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. Mazumder S; Maji M; Ali N PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029 [TBL] [Abstract][Full Text] [Related]
16. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863 [TBL] [Abstract][Full Text] [Related]
18. miR-21 Expression Determines the Early Vaccine Immunity Induced by Gannavaram S; Bhattacharya P; Siddiqui A; Ismail N; Madhavan S; Nakhasi HL Front Immunol; 2019; 10():2273. PubMed ID: 31608064 [TBL] [Abstract][Full Text] [Related]
19. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani. Sharma A; Madhubala R J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862 [TBL] [Abstract][Full Text] [Related]
20. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. Yam KK; Hugentobler F; Pouliot P; Stern AM; Lalande JD; Matlashewski G; Olivier M; Cousineau B J Med Microbiol; 2011 Sep; 60(Pt 9):1248-1260. PubMed ID: 21527547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]